Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX provides a Live Strategy Update on the company’s product portfolio and commercialization strategy on the 12th of October 2021.

October 8, 2021

IR

2cureX AB (publ), an IVD diagnostic company that is pioneering the use of 3D microtumors (tumoroids) to guide the drug treatment of solid cancers, will hold a Live Strategy Update session on 12th October at 13:00 (CET). Presentations will be followed by a Questions & Answers discussion moderated by Redeye’s Equity Analyst, Erik Nordström.

2cureX’s CEO Fernando Andreu, together with Ole Thastrup (CSO), Pia van der Zee (VP of Marketing) and Jesper Floyd Kristiansen (VP of Sales) will present how the unique IndiTreat® platform is addressing a burning issue in oncology, and which strategy and commercialization activities are being conducted to introduce the first IndiTreat® product into the European market.

Link to Strategy Update webcast:

https://www.redeye.se/events/818830/strategy-update-2curex

Link to registration:

https://www.lyyti.fi/reg/Strategy_Update_2cureX

The presentation will be held in English.